NASDAQ:GRI GRI Bio (GRI) Stock Price, News & Analysis → The ONE AI Stock to own now. (It’s not Nvidia.) (From Weiss Ratings) (Ad) Free GRI Stock Alerts 0.30 -0.03 (-8.73%) (As of 05/31/2024 08:50 PM ET) Add Compare Share Share Today's Range0.29▼0.3250-Day Range0.30▼0.7852-Week Range0.29▼47.95Volume185,600 shsAverage Volume542,950 shsMarket Capitalization$1.14 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestTrends Get GRI Bio alerts: Email Address Ad Weiss RatingsOn June 10, Nvidia makes its next big moveA small handful of companies are working with Nvidia to help ensure that this pivot is a massive success. We call them Nvidia’s “Silent Partners.”Click here to find out who they are. About GRI Bio Stock (NASDAQ:GRI)GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.Read More GRI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GRI Stock News HeadlinesMay 23, 2024 | finance.yahoo.comGRI Bio (NASDAQ: GRI) Participates in Virtual Investor CEO ConnectMay 22, 2024 | globenewswire.comGRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment Highlighting Positive Preclinical Data from Idiopathic Pulmonary Fibrosis (IPF) and Systemic Lupus Erythematosus (SLE) ProgramsMay 21, 2024 | globenewswire.comGRI Bio Presents Positive Preclinical Data from Pipeline of NKT Cell Modulators in Development for the Treatment of Systemic Lupus Erythematosus (SLE)May 20, 2024 | finance.yahoo.comGRI Bio Presents Positive Preclinical Data Demonstrating Lead Program GRI-0621 Reduces the Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)May 20, 2024 | globenewswire.comGRI Bio Presents Positive Preclinical Data Demonstrating Lead Program GRI-0621 Reduces the Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)May 15, 2024 | washingtonpost.comZiopharm: Q1 Earnings SnapshotMay 14, 2024 | finance.yahoo.comGRI Bio to Present at Alliance Global Partner’s 2024 Healthcare Company ShowcaseMay 14, 2024 | globenewswire.comGRI Bio to Present at Alliance Global Partner's 2024 Healthcare Company ShowcaseMay 13, 2024 | msn.comGRI Stock Earnings: GRI Bio Reported Results for Q1 2024May 13, 2024 | globenewswire.comGRI Bio Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 2, 2024 | msn.comBabraham-based Harness Therapeutics appoints Meenu Chhabra Karson as board chairApril 29, 2024 | globenewswire.comGRI Bio Announces Abstracts Accepted for Presentation at the 14th International Congress on AutoimmunityApril 25, 2024 | globenewswire.comGRI Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment WebinarApril 18, 2024 | finanznachrichten.deGRI Bio, Inc.: GRI Bio Expands Intellectual Property Protection for Proprietary Natural Killer T (NKT) Cell Modulators with Issuance of Korea PatentApril 16, 2024 | globenewswire.comGRI Bio Expands Intellectual Property Protection for Proprietary Natural Killer T (NKT) Cell Modulators with Issuance of Korea PatentApril 8, 2024 | globenewswire.comGRI Bio Announces Abstract Accepted for Poster Presentation at the 2024 American Thoracic Society International ConferenceApril 1, 2024 | globenewswire.comGRI Bio Reports Full Year 2023 Financial Results and Provides Corporate UpdateMarch 28, 2024 | globenewswire.comGRI Bio to Present at the MedInvest Biotech & Pharma Investor ConferenceMarch 14, 2024 | finanznachrichten.deGRI Bio, Inc.: GRI Bio Announces Notice of Allowance for Canadian Patent Covering Proprietary Natural Killer T (NKT) Cell ModulatorsMarch 14, 2024 | finance.yahoo.comGRI Bio Announces Notice of Allowance for Canadian Patent Covering Proprietary Natural Killer T (NKT) Cell ModulatorsMarch 14, 2024 | globenewswire.comGRI Bio Announces Notice of Allowance for Canadian Patent Covering Proprietary Natural Killer T (NKT) Cell ModulatorsMarch 4, 2024 | finanznachrichten.deGRI Bio, Inc.: GRI Bio Receives MHRA Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in the United KingdomMarch 4, 2024 | globenewswire.comGRI Bio Receives MHRA Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in the United KingdomFebruary 23, 2024 | benzinga.comTop 4 Health Care Stocks That Are Preparing To Pump This Month - ProSomnus (NASDAQ:OSA), GRI Bio (NASDAQ:GRI)February 3, 2024 | msn.comGRI Bio Launches Major Securities Public OfferingSee More Headlines Receive GRI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GRI Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/10/2024Today6/01/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:GRI CUSIPN/A CIK1824293 Webwww.vallon-pharma.com Phone267-607-8255FaxN/AEmployees4Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-13,040,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-548.12% Return on Assets-290.50% Debt Debt-to-Equity RatioN/A Current Ratio2.64 Quick Ratio2.64 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value0.74 per share Price / Book0.41Miscellaneous Outstanding Shares3,770,000Free Float3,662,000Market Cap$1.14 million OptionableNot Optionable Beta-1.55 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesDr. W. Marc Hertz Ph.D. (Age 53)Co-Founder, CEO, President & Director Comp: $842.01kMs. Leanne M. Kelly (Age 47)CFO & Corporate Secretary Comp: $550.93kDr. Vipin Kumar Chaturvedi Ph.D. (Age 64)Co-Founder & Chief Scientific Officer Dr. Albert Agro Ph.d. (Age 59)Chief Medical Officer Key CompetitorsTRACON PharmaceuticalsNASDAQ:TCONCingulateNASDAQ:CINGChina PharmaNYSE:CPHIArtelo BiosciencesNASDAQ:ARTLGenprexNASDAQ:GNPXView All Competitors GRI Stock Analysis - Frequently Asked Questions How have GRI shares performed in 2024? GRI Bio's stock was trading at 2.70 at the start of the year. Since then, GRI stock has decreased by 88.8% and is now trading at 0.30. View the best growth stocks for 2024 here. Are investors shorting GRI Bio? GRI Bio saw a increase in short interest in May. As of May 15th, there was short interest totaling 24,300 shares, an increase of 49.1% from the April 30th total of 16,300 shares. Based on an average trading volume of 285,000 shares, the short-interest ratio is currently 0.1 days. Approximately 0.7% of the company's stock are sold short. View GRI Bio's Short Interest. When is GRI Bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024. View our GRI earnings forecast. How were GRI Bio's earnings last quarter? GRI Bio, Inc. (NASDAQ:GRI) announced its quarterly earnings results on Friday, May, 10th. The company reported ($0.46) earnings per share for the quarter. When did GRI Bio's stock split? Shares of GRI Bio reverse split before market open on Tuesday, January 30th 2024. The 1-7 reverse split was announced on Tuesday, January 30th 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, January 30th 2024. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split. How do I buy shares of GRI Bio? Shares of GRI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GRI) was last updated on 6/1/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaBiden Nomination CANCELED?The Freeport SocietyNvidia is about to pass AppleWeiss RatingsClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProThe Worst is Yet to Come…Porter & CompanyDems have chosen Biden replacement?Paradigm PressShocking: One AI startup's revenue could surge 4,735%Manward Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GRI Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
